세계의 섬유아세포 성장인자 시장 보고서(2025년)

Fibroblast growth factors (FGFs) are a group of signaling proteins essential for regulating cell growth, tissue repair, and development. They primarily promote fibroblast proliferation and differentiation, playing a key role in processes such as wound healing, embryonic development, angiogenesis, and metabolic regulation.

The major product types of fibroblast growth factors include recombinant fibroblast growth factor, purified fibroblast growth factor, endogenous fibroblast growth factor, and others. Recombinant fibroblast growth factor is synthetically produced through genetic engineering techniques to generate large quantities for therapeutic and research purposes. These are categorized by type into palifermin, erdafitinib, infigratinib, futibatinib, and others. FGFs are used in a wide range of applications, including oncology, hematology, wound healing, dermatology, cardiovascular disease, bone and musculoskeletal disorders, and tissue regeneration. The primary end users include pharmaceutical companies, biotechnology firms, research institutes, and others.

The fibroblast growth factors (FGFs) market research report is one of a series of new reports from The Business Research Company that provides fibroblast growth factors (FGFs) market statistics, including the fibroblast growth factors (FGFs) industry global market size, regional shares, competitors with the fibroblast growth factors (FGFs) market share, detailed fibroblast growth factors (FGFs) market segments, market trends, and opportunities, and any further data you may need to thrive in the fibroblast growth factors (FGFs) industry. This fibroblast growth factors (FGFs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fibroblast growth factors (FGFs) market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $1.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. Growth during the historic period can be attributed to the rising demand for regenerative medicine, increased utilization of FGFs in wound healing applications, growing funding for cancer research, advancements in biopharmaceutical innovation, and heightened awareness of the therapeutic potential of fibroblast growth factors (FGFs).

The fibroblast growth factors (FGFs) market size is expected to see rapid growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. Growth in the forecast period is expected to be driven by rising investments in personalized medicine, increased adoption of fibroblast growth factor (FGF)-based therapies, the growing prevalence of chronic diseases, ongoing advancements in biotechnology, and expanding collaborations between pharmaceutical companies and research institutions. Key trends anticipated during this period include progress in targeted drug delivery systems, development of advanced biomaterials for FGF delivery, innovation in gene editing technologies, advancements in sustained-release formulations, and the emergence of novel combination therapies.

The increasing prevalence of chronic diseases is expected to drive the growth of the fibroblast growth factors (FGFs) market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical attention. This rise in chronic illnesses is partly linked to sedentary lifestyles, as reduced physical activity and prolonged sitting heighten the risk of conditions such as heart disease and diabetes. FGFs contribute to managing chronic diseases by facilitating tissue repair and regeneration, making them valuable in the treatment of long-term conditions. They aid healing, slow disease progression, and improve patient outcomes and quality of life. For example, in June 2024, the UK's National Health Service reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia (pre-diabetes) in 2023-an 18% increase from 3,065,825 cases in 2022. This surge underscores the growing need for effective therapies like FGFs. Thus, the rising burden of chronic diseases is fueling demand in the FGFs market.

Major companies in the fibroblast growth factors (FGFs) market are prioritizing the development of technologically advanced products, such as engineered FGF variants, to improve therapeutic efficacy, minimize side effects, and support regenerative treatments for chronic and degenerative conditions. Engineered FGF variants are modified forms of fibroblast growth factors designed to enhance stability, target specificity, and potency, thereby optimizing therapeutic outcomes in tissue repair and disease management. For example, in October 2022, Zhittya Genesis Medicine, a US-based biotechnology firm, introduced an innovative FGF-1 therapy aimed at treating Parkinson's disease. This therapy utilizes intranasal delivery to stimulate angiogenesis and neuronal regeneration within the brain. The FGF-1 treatment represents a promising advancement in slowing disease progression and enhancing quality of life for affected individuals.

In January 2022, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired PeproTech Inc. for approximately $1.85 billion. This acquisition was intended to strengthen Thermo Fisher's capabilities in cell and gene therapy by broadening its portfolio of recombinant proteins, including fibroblast growth factors (FGFs), which are essential components in cell culture media and regenerative medicine applications. PeproTech Inc., also based in the US, is a biotechnology company that specializes in recombinant FGFs for research and regenerative medicine purposes.

Major players in the fibroblast growth factors (fgfs) market are Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Wako Pure Chemical Corporation, Lonza Group AG, Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, 89bio Inc., R&D Systems Inc., ACROBiosystems Co. Ltd., Elabscience Biotechnology Inc., Cell Signaling Technology Inc., BPS Bioscience Inc., Proteintech Group Inc., Akero Therapeutics Inc., MedChemExpress LLC, Defined Bioscience Inc., Gold Biotechnology Inc. (GoldBio), Nucleus Biologics LLC, ZellBio GmbH, Affinity Biosciences Ltd., GeneCards.

North America was the largest region in the fibroblast growth factors (FGFs) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fibroblast growth factors (FGFs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fibroblast growth factors (FGFs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fibroblast growth factors (FGFs) market consists of sales of fibroblast growth factors (FGFs)-based therapeutic proteins, growth factor supplements for cell culture, and related biologics used in wound healing, tissue regeneration, and cosmetic applications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fibroblast Growth Factors (FGFs) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fibroblast growth factors (fgfs) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fibroblast growth factors (fgfs) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fibroblast growth factors (fgfs) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Recombinant Fibroblast Growth Factor; Purified Fibroblast Growth Factor; Endogenous Fibroblast Growth Factor; Other Product Types
• 2) By Type: Palifermin; Erdafitnib; Infigratinib; Futibatinib; Other Types
• 3) By Application: Oncology; Hematology; Wound Healing; Dermatology; Cardiovascular Disease; Bone Disorders; Musculoskeletal Disorders; Tissue Regeneration; Other Applications
• 4) By End User: Pharmaceutical Companies; Research Institutes; Biotechnology Companies; Other End Users
• Subsegments:
• 1) By Recombinant Fibroblast Growth Factor: Recombinant Fibroblast Growth Factor (FGF)-1; Recombinant Fibroblast Growth Factor (FGF)-2; Recombinant Fibroblast Growth Factor (FGF)-7; Recombinant Fibroblast Growth Factor (FGF)-10
• 2) By Purified Fibroblast Growth Factor: Purified Fibroblast Growth Factor (FGF)-1; Purified Fibroblast Growth Factor (FGF)-2; Purified Fibroblast Growth Factor (FGF)-7; Purified Fibroblast Growth Factor (FGF)-21
• 3) By Endogenous Fibroblast Growth Factor: Endogenous Fibroblast Growth Factor (FGF)-1; Endogenous Fibroblast Growth Factor (FGF)-2; Endogenous Fibroblast Growth Factor (FGF)-8; Endogenous Fibroblast Growth Factor (FGF)-23
• 4) By Other Product Types: Synthetic Fibroblast Growth Factors; Modified Fibroblast Growth Factors; Fusion Protein Fibroblast Growth Factors (FGFs); Fibroblast Growth Factors (FGFs) Derived From Stem Cells
• Companies Mentioned: Merck & Co. Inc.; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Novartis AG; FUJIFILM Wako Pure Chemical Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fibroblast Growth Factors (FGFs) Market Characteristics

3. Fibroblast Growth Factors (FGFs) Market Trends And Strategies

4. Fibroblast Growth Factors (FGFs) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fibroblast Growth Factors (FGFs) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fibroblast Growth Factors (FGFs) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fibroblast Growth Factors (FGFs) Market Growth Rate Analysis
• 5.4. Global Fibroblast Growth Factors (FGFs) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fibroblast Growth Factors (FGFs) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fibroblast Growth Factors (FGFs) Total Addressable Market (TAM)

6. Fibroblast Growth Factors (FGFs) Market Segmentation

• 6.1. Global Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Fibroblast Growth Factor
• Purified Fibroblast Growth Factor
• Endogenous Fibroblast Growth Factor
• Other Product Types
• 6.2. Global Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Palifermin
• Erdafitnib
• Infigratinib
• Futibatinib
• Other Types
• 6.3. Global Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Hematology
• Wound Healing
• Dermatology
• Cardiovascular Disease
• Bone Disorders
• Musculoskeletal Disorders
• Tissue Regeneration
• Other Applications
• 6.4. Global Fibroblast Growth Factors (FGFs) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Institutes
• Biotechnology Companies
• Other End Users
• 6.5. Global Fibroblast Growth Factors (FGFs) Market, Sub-Segmentation Of Recombinant Fibroblast Growth Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Fibroblast Growth Factor (FGF)-1
• Recombinant Fibroblast Growth Factor (FGF)-2
• Recombinant Fibroblast Growth Factor (FGF)-7
• Recombinant Fibroblast Growth Factor (FGF)-10
• 6.6. Global Fibroblast Growth Factors (FGFs) Market, Sub-Segmentation Of Purified Fibroblast Growth Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purified Fibroblast Growth Factor (FGF)-1
• Purified Fibroblast Growth Factor (FGF)-2
• Purified Fibroblast Growth Factor (FGF)-7
• Purified Fibroblast Growth Factor (FGF)-21
• 6.7. Global Fibroblast Growth Factors (FGFs) Market, Sub-Segmentation Of Endogenous Fibroblast Growth Factor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endogenous Fibroblast Growth Factor (FGF)-1
• Endogenous Fibroblast Growth Factor (FGF)-2
• Endogenous Fibroblast Growth Factor (FGF)-8
• Endogenous Fibroblast Growth Factor (FGF)-23
• 6.8. Global Fibroblast Growth Factors (FGFs) Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic Fibroblast Growth Factors
• Modified Fibroblast Growth Factors
• Fusion Protein Fibroblast Growth Factors (FGFs)
• Fibroblast Growth Factors (FGFs) Derived From Stem Cells

7. Fibroblast Growth Factors (FGFs) Market Regional And Country Analysis

• 7.1. Global Fibroblast Growth Factors (FGFs) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fibroblast Growth Factors (FGFs) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fibroblast Growth Factors (FGFs) Market

• 8.1. Asia-Pacific Fibroblast Growth Factors (FGFs) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fibroblast Growth Factors (FGFs) Market

• 9.1. China Fibroblast Growth Factors (FGFs) Market Overview
• 9.2. China Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fibroblast Growth Factors (FGFs) Market

• 10.1. India Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fibroblast Growth Factors (FGFs) Market

• 11.1. Japan Fibroblast Growth Factors (FGFs) Market Overview
• 11.2. Japan Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fibroblast Growth Factors (FGFs) Market

• 12.1. Australia Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fibroblast Growth Factors (FGFs) Market

• 13.1. Indonesia Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fibroblast Growth Factors (FGFs) Market

• 14.1. South Korea Fibroblast Growth Factors (FGFs) Market Overview
• 14.2. South Korea Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fibroblast Growth Factors (FGFs) Market

• 15.1. Western Europe Fibroblast Growth Factors (FGFs) Market Overview
• 15.2. Western Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fibroblast Growth Factors (FGFs) Market

• 16.1. UK Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fibroblast Growth Factors (FGFs) Market

• 17.1. Germany Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fibroblast Growth Factors (FGFs) Market

• 18.1. France Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fibroblast Growth Factors (FGFs) Market

• 19.1. Italy Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fibroblast Growth Factors (FGFs) Market

• 20.1. Spain Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fibroblast Growth Factors (FGFs) Market

• 21.1. Eastern Europe Fibroblast Growth Factors (FGFs) Market Overview
• 21.2. Eastern Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fibroblast Growth Factors (FGFs) Market

• 22.1. Russia Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fibroblast Growth Factors (FGFs) Market

• 23.1. North America Fibroblast Growth Factors (FGFs) Market Overview
• 23.2. North America Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fibroblast Growth Factors (FGFs) Market

• 24.1. USA Fibroblast Growth Factors (FGFs) Market Overview
• 24.2. USA Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fibroblast Growth Factors (FGFs) Market

• 25.1. Canada Fibroblast Growth Factors (FGFs) Market Overview
• 25.2. Canada Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fibroblast Growth Factors (FGFs) Market

• 26.1. South America Fibroblast Growth Factors (FGFs) Market Overview
• 26.2. South America Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fibroblast Growth Factors (FGFs) Market

• 27.1. Brazil Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fibroblast Growth Factors (FGFs) Market

• 28.1. Middle East Fibroblast Growth Factors (FGFs) Market Overview
• 28.2. Middle East Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fibroblast Growth Factors (FGFs) Market

• 29.1. Africa Fibroblast Growth Factors (FGFs) Market Overview
• 29.2. Africa Fibroblast Growth Factors (FGFs) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fibroblast Growth Factors (FGFs) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fibroblast Growth Factors (FGFs) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fibroblast Growth Factors (FGFs) Market Competitive Landscape And Company Profiles

• 30.1. Fibroblast Growth Factors (FGFs) Market Competitive Landscape
• 30.2. Fibroblast Growth Factors (FGFs) Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. FUJIFILM Wako Pure Chemical Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Fibroblast Growth Factors (FGFs) Market Other Major And Innovative Companies

• 31.1. Lonza Group AG
• 31.2. Miltenyi Biotec B.V. & Co. KG
• 31.3. GenScript Biotech Corporation
• 31.4. 89bio Inc.
• 31.5. R&D Systems Inc.
• 31.6. ACROBiosystems Co. Ltd.
• 31.7. Elabscience Biotechnology Inc.
• 31.8. Cell Signaling Technology Inc.
• 31.9. BPS Bioscience Inc.
• 31.10. Proteintech Group Inc.
• 31.11. Akero Therapeutics Inc.
• 31.12. MedChemExpress LLC
• 31.13. Defined Bioscience Inc.
• 31.14. Gold Biotechnology Inc. (GoldBio)
• 31.15. Nucleus Biologics LLC

32. Global Fibroblast Growth Factors (FGFs) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fibroblast Growth Factors (FGFs) Market

34. Recent Developments In The Fibroblast Growth Factors (FGFs) Market

35. Fibroblast Growth Factors (FGFs) Market High Potential Countries, Segments and Strategies

• 35.1 Fibroblast Growth Factors (FGFs) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fibroblast Growth Factors (FGFs) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fibroblast Growth Factors (FGFs) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer